ArticleMicroorganisms2020
SARS-CoV-2 Inhibition by Sulfonated Compounds.
Article in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Novel Wide-Spectrum Virucidal Lipid Nanoparticles.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo.Science advances · 2025Article
- Pathogen-binding nanoparticles to inhibit host cell infection by heparan sulfate and sialic acid dependent viruses and protozoan parasites.Smart medicine · 2024Review
- Benzene with Alkyl Chains Is a Universal Scaffold for Multivalent Virucidal Antivirals.ACS central science · 2024Article
- Antiviral activity of marine sulfated glycans against pathogenic human coronaviruses.Scientific reports · 2023Article
- Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing.Synthetic and systems biotechnology · 2023Review
- Non-anticoagulant heparin derivatives for COVID-19 treatment.International journal of biological macromolecules · 2023Review
- Potent Virustatic Polymer-Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo.ACS central science · 2022Article
- Polyelectrolyte Membrane Nanocoatings Aimed at Personal Protective and Medical Equipment Surfaces to Reduce Coronavirus Spreading.Membranes · 2022Article
- Review
- Macromolecular Viral Entry Inhibitors as Broad-Spectrum First-Line Antivirals with Activity against SARS-CoV-2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Article
- Review
- Computational Insight on the Interaction of Common Blood Proteins with Gold Nanoparticles.International journal of molecular sciences · 2021Article
- Viruses Like Sugars: How to Assess Glycan Involvement in Viral Attachment.Microorganisms · 2021Review
- Recent Advances on Nanomaterials to COVID-19 Management: A Systematic Review on Antiviral/Virucidal Agents and Mechanisms of SARS-CoV-2 Inhibition/Inactivation.Global challenges (Hoboken, NJ) · 2021Review
- Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019.Frontiers in microbiology · 2021Review
- Clinical severe acute respiratory syndrome coronavirus 2 isolation and antiviral testing.Antiviral chemistry & chemotherapyArticle
- The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review.Clinical epidemiology and global healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) depends on angiotensin converting enzyme 2 (ACE2) for cellular entry, but it might also rely on attachment receptors such as heparan sulfates. Several groups have recently demonstrated an affinity of the SARS-CoV2 spike protein for heparan sulfates and a reduced binding to cells in the presence of heparin or heparinase treatment. Here, we investigated the inhibitory activity of several sulfated and sulfonated molecules, which prevent interaction with heparan sulfates, against vesicular stomatitis virus (VSV)-pseudotyped-SARS-CoV-2 and the authentic SARS-CoV-2. Sulfonated cyclodextrins and nanoparticles that have recently shown broad-spectrum non-toxic virucidal activity against many heparan sulfates binding viruses showed inhibitory activity in the micromolar and nanomolar ranges, respectively. In stark contrast with the mechanisms that these compounds present for these other viruses, the inhibition against SARS-CoV-2 was found to be simply reversible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.